Author Affiliations: Department of Medicine, Massachusetts General Hospital (MGH) Center for Global Health, Boston (Drs Bangsberg and Haberer); Department of Global Health and Social Medicine, Harvard Medical School, Boston (Drs Bangsberg and Haberer); Ragon Institute of MGH, Massachusetts Institute of Technology, and Harvard, Charlestown (Dr Bangsberg); and Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda (Dr Bangsberg).
Modern, potent antiretroviral therapy regimens can suppress human immunodeficiency virus (HIV) replication indefinitely. For those who have access to these drugs and who are able to adhere on a daily basis to these drugs, life expectancy now approaches that of individuals without HIV infection, particularly if they start therapy early.1,2 Full lifetime viral suppression offers the potentially transformative public health benefit of reducing transmission leading to a decline in number of new HIV infections.3
Bangsberg DR, Haberer JE. Lifetime HIV Antiretroviral Therapy Adherence Intervention: Timing Is Everything: Comment on “Managed Problem Solving for Antiretroviral Therapy Adherence”. JAMA Intern Med. 2013;173(4):306–307. doi:10.1001/jamainternmed.2013.2858
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: